In a March 27 PRNewswire press release, Bioness, Inc. announced that insurer, Aetna, will cover their StimRouter Neuromodulation System for patients that meet the proper criteria for intractable neurogenic pain.
According to Todd Cushman, President and CEO of Bioness, “Payers look at the long-term impact and cost effectiveness of devices closely when determining whether or not to extend coverage to members. Up until now patients suffering from intractable neurogenic pain have had limited treatment options and often had to pay for care that is considered experimental out of pocket.”
“With this coverage, Aetna now considers the StimRouter medically necessary durable medical equipment (DME) for members with intractable neurogenic pain, also known as chronic pain of a peripheral nerve origin.”
“StimRouter was the first FDA cleared, minimally invasive, long-term, neuromodulation medical device indicated to treat chronic pain of a peripheral nerve origin.”, and as we reported last September, differs from traditional neuromodulation products like Spinal Cord Stimulators in several ways, the most significant being the removal of the large battery and pulse generator to outside the body, allowing the implantation of the small, 15cm lead to be completed in 15-30 minutes while the patient is awake. Other products require a “trial lead” or removal of the lead after 30 days, amounting to a second surgery. With the StimRouter the trial and implant are combined in one surgical procedure.
As the third largest private insurer in the United States, Aetna’s “decision to provide coverage of the StimRouter opens the door to a new treatment option for those members that are suffering from chronic peripheral nerve pain.”
According to the StimRouter website, Indications For Use are, “the StimRouter™ Neuromodulation System is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as an adjunct to other modes of therapy (e.g., medications). The StimRouter is not intended to treat pain in the craniofacial region.”
The full press release can be found here.
More information on this device, as well as Precautions, Warnings and Contraindications can be found at http://www.stimrouter.com/information.php